Symbols / RFL Stock $1.34 +0.75% Rafael Holdings, Inc.

Real Estate • Real Estate Services • United States • NYQ
RFL (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Real Estate
Industry Real Estate Services
CEO Mr. Howard S. Jonas
Exch · Country NYQ · United States
Market Cap 69.70M
Enterprise Value 36.67M
Income -33.11M
Sales 1.16M
FCF (ttm) 184.25K
Book/sh 1.52
Cash/sh 0.73
Employees 21
Insider 10d —
IPO Mar 27, 2018
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E —
PEG —
P/S 59.93
P/B 0.88
P/C —
EV/EBITDA -1.06
EV/Sales 31.53
Quick Ratio 3.08
Current Ratio 3.44
Debt/Eq 0.79
LT Debt/Eq —
EPS (ttm) -0.79
EPS next Y —
EPS Growth —
Revenue Growth 174.00%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-06-10
Earnings (prior) —
ROA -23.77%
ROE -41.37%
ROIC —
Gross Margin 93.12%
Oper. Margin -31.54%
Profit Margin 0.00%
Shs Outstand 51.22M
Shs Float 35.60M
Insider Own 37.85%
Instit Own 7.33%
Short Float 0.20%
Short Ratio 0.75
Short Interest 44.05K
52W High 3.19
vs 52W High -57.99%
52W Low 1.12
vs 52W Low 19.64%
Beta 0.49
Impl. Vol. 1.89%
Rel Volume 0.15
Avg Volume 79.49K
Volume 12.04K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $1.33
Price $1.34
Change 0.75%
About

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is Trappsol Cyclo, which is in phase 3 clinical trial being evaluated for the potential treatment of Niemann-Pick Disease Type C1 ("NPC1"), a rare, fatal and progressive genetic disorder; and CPI-613 (devimistat), a stable analog of normally transient, acylated catalytic intermediates of lipoate, which is in phase II of clinical trial. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1A and 1B clinical studies targeting patients with advanced cancers. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrument for Carpal Tunnel syndrome. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$1.34
Latest analyst target
3. DCF / Fair value
$0.06
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.34
Low
—
High
—
Mean
—
News
RSS: Latest RFL news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-01-28 WEISS MICHAEL J Director — 39,370 $1.27 $50,000
2026-01-28 SIEGER MARKUS Director — 29,528 $1.27 $37,501
2026-01-28 STEIN MARK N. Director — 39,370 $1.27 $50,000
2026-01-28 GRAYSON ALAN Director — 6,562 $1.27 $8,334
2026-01-13 JONAS HOWARD S Chief Executive Officer — 75,000 $1.25 $93,638
2026-01-13 POLINSKY DAVID Chief Financial Officer — 50,000 $1.25 $62,425
2025-05-29 POLINSKY DAVID Chief Financial Officer — 76,882 $1.28 $98,409
2025-05-27 SIEGER MARKUS Director — 35,000 $1.28 $44,800
2025-03-25 CONKLING WILLIAM Chief Executive Officer — 27,454 $0.00 $0
2025-01-13 POLINSKY DAVID Chief Financial Officer — 50,000 $1.95 $97,700
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Total Revenue
0.64
+128.32%
0.28
-31.95%
0.41
-48.88%
0.80
Operating Revenue
0.64
+128.32%
0.28
-31.95%
0.41
-48.88%
0.80
Cost Of Revenue
0.15
0.00
—
—
Reconciled Cost Of Revenue
0.15
0.00
—
—
Gross Profit
0.48
+73.12%
0.28
—
—
Operating Expense
103.11
+572.95%
15.32
-74.84%
60.89
+176.75%
22.00
Research And Development
94.03
+1389.72%
6.31
-27.80%
8.74
+78.15%
4.91
Selling General And Administration
8.85
-0.87%
8.93
-47.39%
16.98
-0.27%
17.02
General And Administrative Expense
8.85
-0.87%
8.93
-47.39%
16.98
—
Other Gand A
8.85
-0.87%
8.93
-47.39%
16.98
—
Total Expenses
103.26
+573.96%
15.32
-74.84%
60.89
+176.75%
22.00
Operating Income
-102.63
-582.22%
-15.04
+75.13%
-60.48
-185.28%
-21.20
Total Operating Income As Reported
-102.63
-582.22%
-15.04
+75.13%
-60.48
-114.47%
-28.20
EBITDA
-66.79
-670.60%
-8.67
+93.80%
-139.89
-499.27%
-23.34
Normalized EBITDA
-68.60
-485.69%
-11.71
+80.55%
-60.20
-184.96%
-21.13
Reconciled Depreciation
0.23
+188.46%
0.08
+8.33%
0.07
+2.86%
0.07
EBIT
-67.01
-666.30%
-8.74
+93.75%
-139.97
-497.79%
-23.41
Total Unusual Items
1.81
-40.62%
3.04
+103.82%
-79.69
-3494.50%
-2.22
Total Unusual Items Excluding Goodwill
1.81
-40.62%
3.04
+103.82%
-79.69
-3494.50%
-2.22
Special Income Charges
-1.63
-388.92%
-0.33
+99.58%
-79.14
-924.61%
-7.72
Other Special Charges
89.86
—
—
—
Restructuring And Mergern Acquisition
1.63
0.00
—
—
Write Off
0.00
-100.00%
0.33
-99.58%
79.14
+924.61%
7.72
Net Income
-34.41
-1734.22%
-1.88
+98.50%
-124.66
-407.90%
-24.54
Pretax Income
-67.26
-669.14%
-8.74
+93.75%
-139.97
-497.51%
-23.43
Net Non Operating Interest Income Expense
2.13
-34.37%
3.25
+1568.21%
0.20
+2050.00%
-0.01
Interest Expense Non Operating
0.25
0.00
-100.00%
0.01
-50.00%
0.01
Net Interest Income
2.13
-34.37%
3.25
+1568.21%
0.20
+2050.00%
-0.01
Interest Expense
0.25
0.00
-100.00%
0.01
-50.00%
0.01
Interest Income Non Operating
2.38
-26.74%
3.25
+1518.41%
0.20
+9950.00%
0.00
Interest Income
2.38
-26.74%
3.25
+1518.41%
0.20
+9950.00%
0.00
Other Income Expense
33.23
+991.33%
3.04
+103.82%
-79.69
-3494.50%
-2.22
Other Non Operating Income Expenses
31.42
—
—
—
Gain On Sale Of Security
3.44
+1.83%
3.38
+715.48%
-0.55
-109.97%
5.51
Tax Provision
-2.68
-950.98%
-0.26
0.00
-100.00%
0.02
Tax Rate For Calcs
0.00
+36.64%
0.00
0.00
-100.00%
0.00
Tax Effect Of Unusual Items
0.07
-18.87%
0.09
0.00
+100.00%
-0.60
Net Income Including Noncontrolling Interests
-65.00
-2834.67%
-2.21
+98.44%
-142.38
-474.89%
-24.77
Net Income From Continuing Operation Net Minority Interest
-34.41
-311.90%
-8.35
+93.20%
-122.83
-437.80%
-22.84
Net Income From Continuing And Discontinued Operation
-34.41
-1734.22%
-1.88
+98.50%
-124.66
-407.90%
-24.54
Net Income Continuous Operations
-65.00
-647.76%
-8.69
+93.81%
-140.55
-509.46%
-23.06
Net Income Discontinuous Operations
0.00
-100.00%
6.48
+453.99%
-1.83
-7.33%
-1.71
Minority Interests
30.59
+8924.48%
0.34
-98.09%
17.72
+7881.53%
0.22
Normalized Income
-36.15
-219.59%
-11.31
+73.78%
-43.14
-103.28%
-21.22
Net Income Common Stockholders
-34.41
-1734.22%
-1.88
+98.50%
-124.66
-407.90%
-24.54
Diluted EPS
-1.43
-1712.49%
-0.08
+98.73%
-6.22
—
Basic EPS
-1.43
-1712.49%
-0.08
+98.73%
-6.22
—
Basic Average Shares
24.09
+6.66%
22.58
+12.63%
20.05
—
Diluted Average Shares
24.09
+6.66%
22.58
+12.63%
20.05
—
Diluted NI Availto Com Stockholders
-34.41
-1734.22%
-1.88
+98.50%
-124.66
-407.90%
-24.54
Depreciation Amortization Depletion Income Statement
0.23
+188.46%
0.08
+8.33%
0.07
+2.86%
0.07
Depreciation And Amortization In Income Statement
0.23
+188.46%
0.08
+8.33%
0.07
+2.86%
0.07
Earnings From Equity Interest Net Of Tax
-0.42
-107.88%
-0.20
+64.70%
-0.57
-250.13%
0.38
Gain On Sale Of PPE
—
—
—
0.75
Net Income Extraordinary
—
—
—
0.00
Provision For Doubtful Accounts
—
0.00
-100.00%
35.09
0.00
Total Other Finance Cost
—
—
—
0.10
Line Item Trend 2024-07-31 2023-07-31 2021-07-31
Total Assets
96.83
-2.02%
98.83
-35.85%
154.06
Current Assets
72.50
-12.59%
82.94
+461.78%
14.76
Cash Cash Equivalents And Short Term Investments
65.94
-17.06%
79.51
+912.30%
7.85
Cash And Cash Equivalents
2.67
-87.56%
21.50
+173.72%
7.85
Other Short Term Investments
63.27
+9.06%
58.01
0.00
Receivables
6.13
+143.24%
2.52
+201.92%
0.83
Accounts Receivable
0.43
+100.00%
0.21
-9.36%
0.23
Gross Accounts Receivable
0.67
+46.51%
0.46
+7.01%
0.43
Allowance For Doubtful Accounts Receivable
-0.24
+0.00%
-0.24
-26.94%
-0.19
Accrued Interest Receivable
0.52
+33.07%
0.39
0.00
Prepaid Assets
—
—
1.07
Restricted Cash
—
—
5.00
Assets Held For Sale Current
—
0.00
0.00
Other Current Assets
0.43
-52.95%
0.91
-14.98%
1.07
Total Non Current Assets
24.33
+53.13%
15.89
-88.59%
139.29
Net PPE
2.12
+25.07%
1.70
-7.88%
1.84
Gross PPE
3.14
+21.96%
2.57
+0.08%
2.57
Accumulated Depreciation
-1.02
-15.95%
-0.88
-20.11%
-0.73
Properties
0.00
0.00
0.00
Land And Improvements
—
—
10.41
Buildings And Improvements
2.50
+0.00%
2.50
+0.00%
2.50
Machinery Furniture Equipment
0.55
0.00
-100.00%
1.15
Other Properties
0.08
+19.12%
0.07
+3.03%
0.07
Goodwill And Other Intangible Assets
6.47
+310.92%
1.57
+0.00%
1.57
Goodwill
3.05
0.00
—
Other Intangible Assets
3.42
+117.27%
1.57
+0.00%
1.57
Investments And Advances
12.01
+57.51%
7.62
-90.49%
80.19
Long Term Equity Investment
12.01
+152.15%
4.76
+728.35%
0.57
Other Investments
0.00
-100.00%
2.86
+500.00%
0.48
Non Current Accounts Receivable
—
—
7.50
Non Current Deferred Assets
—
—
0.00
Non Current Deferred Taxes Assets
—
—
0.00
Other Non Current Assets
0.04
+288.89%
0.01
-99.98%
42.91
Total Liabilities Net Minority Interest
10.57
+380.64%
2.20
-87.32%
17.35
Current Liabilities
7.51
+250.30%
2.15
-87.60%
17.30
Payables And Accrued Expenses
5.09
+353.39%
1.12
-55.53%
2.52
Payables
3.29
+816.16%
0.36
-72.30%
1.30
Accounts Payable
2.56
+667.57%
0.33
-71.29%
1.16
Current Accrued Expenses
1.80
+135.65%
0.76
-37.82%
1.23
Current Debt And Capital Lease Obligation
2.31
—
14.53
Current Debt
2.31
—
14.53
Other Current Borrowings
0.61
—
14.53
Other Current Liabilities
0.11
-88.95%
1.02
+305.95%
0.25
Total Non Current Liabilities Net Minority Interest
3.06
+5463.64%
0.06
+14.58%
0.05
Long Term Debt And Capital Lease Obligation
0.07
—
—
Long Term Debt
0.07
—
—
Other Non Current Liabilities
0.01
-90.91%
0.06
+14.58%
0.05
Stockholders Equity
82.19
-18.06%
100.29
-17.98%
122.29
Common Stock Equity
82.19
-18.06%
100.29
-17.98%
122.29
Capital Stock
0.25
+0.82%
0.24
+37.85%
0.18
Common Stock
0.25
+0.82%
0.24
+37.85%
0.18
Share Issued
25.06
+1.17%
24.77
+37.72%
17.99
Ordinary Shares Number
24.96
+1.36%
24.63
+36.98%
17.98
Treasury Shares Number
0.10
-30.10%
0.15
+1323.12%
0.01
Additional Paid In Capital
280.05
+6.07%
264.01
+65.90%
159.14
Retained Earnings
-201.74
-20.56%
-167.33
-310.14%
-40.80
Gains Losses Not Affecting Retained Earnings
3.80
+12.75%
3.37
-10.60%
3.77
Treasury Stock
0.17
0.00
—
Minority Interest
4.07
+211.16%
-3.66
-125.41%
14.42
Other Equity Adjustments
—
—
3.77
Total Equity Gross Minority Interest
86.26
-10.73%
96.63
-29.32%
136.70
Total Capitalization
82.26
-17.98%
100.29
-17.98%
122.29
Working Capital
64.99
-19.57%
80.80
+3282.20%
-2.54
Invested Capital
84.57
-15.68%
100.29
-26.69%
136.81
Total Debt
2.39
—
14.53
Net Debt
—
—
6.67
Net Tangible Assets
75.71
-23.30%
98.72
-18.22%
120.71
Tangible Book Value
75.71
-23.30%
98.72
-18.22%
120.71
Available For Sale Securities
—
4.76
—
Current Notes Payable
1.70
0.00
-100.00%
14.53
Duefrom Related Parties Current
—
—
0.60
Duefrom Related Parties Non Current
—
—
7.50
Dueto Related Parties Current
0.73
+2719.23%
0.03
-80.88%
0.14
Financial Assets
2.55
-48.90%
4.98
-5.39%
5.27
Foreign Currency Translation Adjustments
3.69
-0.91%
3.73
-1.25%
3.77
Interest Payable
0.21
0.00
—
Investmentin Financial Assets
—
4.76
-93.98%
79.14
Investments In Other Ventures Under Equity Method
—
—
0.48
Investmentsin Associatesat Cost
12.01
+152.15%
4.76
+728.35%
0.57
Investmentsin Joint Venturesat Cost
—
2.80
—
Investmentsin Subsidiariesat Cost
—
—
79.14
Non Current Accrued Expenses
2.98
0.00
—
Non Current Note Receivables
1.15
0.00
—
Notes Receivable
5.19
+170.22%
1.92
—
Unrealized Gain Loss
0.11
+131.44%
-0.35
0.00
Line Item Trend 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Operating Cash Flow
-7.80
+28.33%
-10.89
+58.26%
-26.08
-67.16%
-15.60
Cash Flow From Continuing Operating Activities
-7.80
+23.86%
-10.25
+63.23%
-27.87
-81.98%
-15.31
Cash From Discontinued Operating Activities
0.00
+100.00%
-0.64
-1458.54%
-0.04
+85.71%
-0.29
Net Income From Continuing Operations
-65.00
-647.76%
-8.69
+93.89%
-142.38
-517.39%
-23.06
Depreciation Amortization Depletion
0.23
+188.46%
0.08
+8.33%
0.07
+2.86%
0.07
Depreciation
—
0.08
+8.33%
0.07
—
Depreciation And Amortization
0.23
+188.46%
0.08
+8.33%
0.07
+2.86%
0.07
Other Non Cash Items
60.19
+1029.13%
-6.48
-453.99%
1.83
+6435.71%
0.03
Pension And Employee Benefit Expense
—
—
—
6.63
Stock Based Compensation
2.30
+4.94%
2.19
+338.60%
-0.92
-113.82%
6.63
Provisionand Write Offof Assets
—
0.00
-100.00%
35.10
+18086.01%
0.19
Asset Impairment Charge
0.02
-94.01%
0.33
-99.58%
79.14
+924.61%
7.72
Deferred Tax
—
—
0.00
-100.00%
0.01
Deferred Income Tax
—
—
0.00
-100.00%
0.01
Operating Gains Losses
-1.80
-952.63%
-0.17
-115.21%
1.12
+119.08%
-5.89
Gain Loss On Investment Securities
-2.21
-491.71%
-0.37
-168.12%
0.55
+111.54%
-4.76
Unrealized Gain Loss On Investment Securities
-1.23
+54.45%
-2.70
0.00
+100.00%
-4.76
Gain Loss On Sale Of PPE
-0.03
0.00
0.00
+100.00%
-0.75
Change In Working Capital
-0.61
-563.04%
-0.09
-820.00%
-0.01
+98.99%
-0.99
Change In Receivables
-0.29
+20.60%
-0.36
-95.70%
-0.19
+71.07%
-0.64
Changes In Account Receivables
-0.15
-28.21%
-0.12
-258.11%
0.07
+145.96%
-0.16
Change In Prepaid Assets
0.67
+80.43%
0.37
+110.52%
-3.54
-342.02%
-0.80
Change In Payables And Accrued Expense
-0.01
+99.08%
-0.87
-5700.00%
-0.01
-105.00%
0.30
Change In Accrued Expense
—
—
—
0.00
Change In Payable
-0.01
+99.08%
-0.87
-5700.00%
-0.01
-105.00%
0.30
Change In Account Payable
-0.15
+82.35%
-0.83
-1690.38%
0.05
-68.29%
0.16
Change In Other Working Capital
—
—
—
0.14
Change In Other Current Assets
0.02
+181.48%
-0.03
-120.77%
0.13
+106.35%
0.06
Change In Other Current Liabilities
-1.01
-226.63%
0.80
-77.93%
3.61
+3777.42%
0.09
Investing Cash Flow
-10.82
-151.01%
21.21
+133.25%
-63.80
-680.76%
-8.17
Cash Flow From Continuing Investing Activities
-10.82
+59.87%
-26.96
+57.67%
-63.68
-703.98%
-7.92
Cash From Discontinued Investing Activities
0.00
-100.00%
48.17
+42729.20%
-0.11
+54.80%
-0.25
Net PPE Purchase And Sale
-0.14
0.00
+100.00%
-0.00
-100.05%
3.70
Purchase Of PPE
-0.14
0.00
+100.00%
-0.00
+99.03%
-0.21
Sale Of PPE
—
—
0.00
-100.00%
3.70
Capital Expenditure
-0.18
—
-0.00
+99.03%
-0.21
Net Investment Purchase And Sale
-6.28
+74.85%
-24.96
+32.18%
-36.81
0.00
Purchase Of Investment
-162.44
+23.19%
-211.48
-223.84%
-65.31
0.00
Sale Of Investment
156.16
-16.28%
186.52
+554.47%
28.50
0.00
Net Business Purchase And Sale
2.35
0.00
0.00
-100.00%
5.00
Purchase Of Business
—
-5.10
0.00
+100.00%
-2.00
Gain Loss On Sale Of Business
0.02
0.00
—
—
Net Intangibles Purchase And Sale
0.23
0.00
—
—
Purchase Of Intangibles
-0.04
0.00
—
—
Net Other Investing Changes
-6.99
-249.45%
-2.00
+92.56%
-26.88
-61.67%
-16.62
Financing Cash Flow
-0.18
+98.82%
-15.22
-114.65%
103.86
+242.81%
30.30
Cash Flow From Continuing Financing Activities
-0.18
+17.89%
-0.22
-100.21%
103.86
+557.45%
15.80
Net Issuance Payments Of Debt
-0.80
0.00
—
15.00
Issuance Of Debt
—
—
—
15.00
Repayment Of Debt
-0.80
0.00
—
—
Long Term Debt Issuance
—
—
—
15.00
Net Long Term Debt Issuance
—
—
—
15.00
Short Term Debt Payments
-0.80
0.00
—
—
Net Short Term Debt Issuance
-0.80
0.00
—
—
Net Common Stock Issuance
-0.17
0.00
-100.00%
110.17
+747.44%
13.00
Common Stock Payments
-0.17
0.00
—
—
Repurchase Of Capital Stock
-0.17
0.00
—
—
Proceeds From Stock Option Exercised
—
—
0.00
-100.00%
2.07
Net Other Financing Charges
0.79
+461.93%
-0.22
+96.54%
-6.30
-966.99%
0.73
Changes In Cash
-18.80
-284.24%
-4.89
-134.98%
13.99
+114.36%
6.53
Effect Of Exchange Rate Changes
-0.02
+84.93%
-0.15
+52.29%
-0.31
-350.82%
0.12
Beginning Cash Position
21.50
-18.99%
26.54
+106.45%
12.85
+107.12%
6.21
End Cash Position
2.67
-87.56%
21.50
-18.99%
26.54
+106.45%
12.85
Free Cash Flow
-7.98
+26.69%
-10.89
+58.26%
-26.08
-67.18%
-15.60
Amortization Of Securities
-1.89
-58.24%
-1.20
0.00
—
Change In Interest Payable
—
—
—
0.00
Common Stock Issuance
—
0.00
-100.00%
110.17
+747.44%
13.00
Earnings Losses From Equity Investments
0.42
+107.88%
0.20
-64.70%
0.57
+250.13%
-0.38
Issuance Of Capital Stock
—
0.00
-100.00%
110.17
+747.44%
13.00
Sale Of Business
2.35
0.00
0.00
-100.00%
7.00
Sale Of Intangibles
0.27
0.00
—
—
Cash From Discontinued Financing Activities
0.00
+100.00%
-15.00
0.00
-100.00%
14.50
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category